The Effect of Melatonin and Vitamin C on COVID-19
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Pennsylvania
-
Lancaster, Pennsylvania, United States, 17602
- Lancaster General Health
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria
- COVID-19 positive test (outpatient testing),
- Age >50 (chosen based greater risk for older patients to be vitamin deficient, age >65 not used so as not to be too restrictive in the inclusion criteria)
- Experiencing symptoms for <5 days prior to enrollment
- Able to read and write in English or Spanish
- Able to access REDCap daily
- Valid email address
- Current has a Lancaster General Health primary care physician
Exclusion Criteria
- COVID-19 test ordered pre-procedure for asymptomatic screening
- Currently taking vitamin C supplements
- Currently taking melatonin supplements
- Currently hospitalized
- Deceased
- Currently pregnant
- Currently incarcerated
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Experimental- Melatonin
Patients will receive melatonin
|
10mg melatonin, at bedtime
Daily symptom survey to be completed by patient electronically
|
|
Experimental: Experimental- Vit C
Patients will receive vitamin C
|
Daily symptom survey to be completed by patient electronically
1000mg Vitamin C, at bedtime
Other Names:
|
|
Placebo Comparator: Control
Patients will receive placebo
|
Daily symptom survey to be completed by patient electronically
Placebo at bedtime
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Symptom Severity
Time Frame: 14 days
|
Symptom severity will be tracked electronically
|
14 days
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Symptom progression
Time Frame: 14 days
|
Determine symptom course of those with moderate or severe symptoms
|
14 days
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Corey Fogleman, Penn Medicine Lancaster General Health
- Principal Investigator: Corey Fogleman, MD, Physician
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Coronavirus Infections
- Coronaviridae Infections
- Nidovirales Infections
- RNA Virus Infections
- Virus Diseases
- Infections
- Respiratory Tract Infections
- Respiratory Tract Diseases
- Pneumonia, Viral
- Pneumonia
- Lung Diseases
- Severe Acute Respiratory Syndrome
- COVID-19
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Central Nervous System Depressants
- Protective Agents
- Micronutrients
- Vitamins
- Antioxidants
- Melatonin
- Ascorbic Acid
Other Study ID Numbers
Other Study ID Numbers
- 2020-68
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.